Program
Fulvestrant
Also written as “PF-07104091 + PF-07220060 + fulvestrant dose expansion”, “fulvestrant” and “faslodex 500mg”.
Its studies are mostly in Breast Neoplasms · Neoplasms · Carcinoma, Intraductal, Noninfiltrating · Puberty, Precocious · Endometrial Neoplasms, led by 5 companies.
Drug pageFulvestrant: every studyMany companies study it; this page follows only the 25 they lead. All 122 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 211 open or running | phase 4since May 4, 2015 | Jul 21, 2003 | none ahead |
| Atossa Therapeuticsits history only | 10 open or running | phase 2since Aug 28, 2015 | Aug 28, 2015 | none ahead |
| Criterium | 11 open or running | phase 2since Sep 3, 2020 | Sep 3, 2020 | Dec 31, 2027phase 2 · NCT04567420 |
| Eagle Pharmaceuticalsits history only | 10 open or running | phase 1since Oct 24, 2017 | Oct 24, 2017 | none ahead |
| Fresenius Kabiits history only | 10 open or running | phase 1since May 30, 2016 | May 30, 2016 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Criterium only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 3, 2020First study: phase 2 study in Breast NeoplasmsFirst studyNCT04567420 · 70 enrolled · United States
Ahead
- Dec 31, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT04567420
TargetBeta
“Estrogen receptor alpha antagonist; Estrogen receptor degrader”ChEMBL 37, by rule
Other programs on ESR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ethinyl Estradiolrule | Johnson & Johnson | phase 4 | 70 |
| Estradiolrule | Novo Nordisk | phase 4 | 69 |
| Tamoxifenrule | AstraZeneca | phase 4 | 21 |
| Clomiphenerule | Hamad Medical | phase 4 | 3 |
| vepdegestrantrule | Pfizer | phase 3 | 20 |
| camizestrantrule | AstraZeneca | phase 3 | 18 |
| giredestrant | Hoffmann-La Roche | phase 3 | 17 |
| HRS-8080 | Jiangsu HengRui Medicine | phase 3 | 13 |
| elacestrantrule | Menarini Group | phase 3 | 12 |
| Imlunestrantrule | Eli Lilly | phase 3 | 12 |
| taragarestrantrule | InventisBio | phase 3 | 5 |
| SIM0270rule | Simcere Pharmaceutical Group | phase 3 | 5 |
Studies
The one study Criterium leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04567420Breast Neoplasms · United States | 2 | Active, not recruiting | Dec 31, 2027 | 70 |
How it is read
Names in the registry
- “Fulvestrant”, 26 entries
- “PF-07104091 + PF-07220060 + fulvestrant dose expansion”, 2 entries
- “fulvestrant”, 2 entries
- “faslodex 500mg”, 1 entry
- “Fulvestrant injection”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 23 studies
- Neoplasms, 1 study
- Carcinoma, Intraductal, Noninfiltrating, 1 study
- Puberty, Precocious, 1 study
- Endometrial Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.